A Trial of CV301 in Combination With Anti-PD-1 Therapy in Subjects With Non-Small Cell Lung Cancer
A Phase 1 Trial of CV301 in Combination With Anti- PD-1 Therapy in Subjects With Non-Small Cell Lung Cancer
Sponsor: Bavarian Nordic
This PHASE1 trial investigates Non-small Cell Lung Cancer (NSCLC) and is currently completed. Bavarian Nordic leads this study, which shows 14 recorded versions since 2016 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
14 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Mar 2020 — Jan 2021 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
▶ Show 9 earlier versions
-
Dec 2019 — Mar 2020 [monthly]
Active Not Recruiting PHASE1
-
Apr 2019 — Dec 2019 [monthly]
Active Not Recruiting PHASE1
-
Nov 2018 — Apr 2019 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting · Phase: PHASE1_PHASE2 → PHASE1
-
Jul 2018 — Nov 2018 [monthly]
Recruiting PHASE1_PHASE2
-
Jun 2018 — Jul 2018 [monthly]
Recruiting PHASE1_PHASE2
-
May 2018 — Jun 2018 [monthly]
Recruiting PHASE1_PHASE2
-
Oct 2017 — May 2018 [monthly]
Recruiting PHASE1_PHASE2
-
Feb 2017 — Oct 2017 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jan 2017 — Feb 2017 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Dec 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bavarian Nordic
For direct contact, visit the study record on ClinicalTrials.gov .